EU starts rolling review of GSK's antibody for COVID-19

The EMA has begun a rolling review of a COVID-19 antibody developed by GlaxoSmithKline and Vir BioTech which could become the fourth drug of its type cleared for early use in the EU. 

Merck gets confirmatory trial win for Keytruda in endometria...

Merck & Co’s conditional FDA approval for checkpoint inhibitor Keytruda in endometrial cancer looks secure, thanks to a survival benefit in a confirmatory phase 3 trial. 

FTC clears Mylan merger with Pfizer’s Upjohn – with conditio...

Mylan’s $12 billion takeover of Pfizer’s Upjohn unit has been cleared by the US authorities, but on the condition that the two companies divest various generic drug products.

FDA’s review date for BMS’ ide-cel sneaks under the CVR wire

The FDA has given a 27 March 2021 review date for Bristol-Myers Squibb’s multiple myeloma cell therapy ide-cel, just in time to meet a contingent value right (CVR) due to Celgene shareholde

Saunders steps aside as AbbVie closes in on Allergan merger

Lawmaker weighs in on Gottlieb switch to industry